AstraZeneca vaccine found to be 79% effective in U.S. trial, ‘no increased risk’ of blood clots

Business

A healthcare professional draws up a dose of the Oxford/AstraZeneca Covid-19 vaccine at the vaccination centre set up inside Brighton Centre in Brighton, southern England, on January 26, 2021.
Ben Stensall | AFP | Getty Images

LONDON — The findings of a large U.S. trial have shown that the coronavirus vaccine developed by AstraZeneca and the University of Oxford is 79% effective in preventing symptomatic illness and 100% against severe disease and hospitalization.

The results were published Monday

It comes shortly after a flurry of countries temporarily suspended use of the shot following reports of blood clots in some vaccinated people.

Germany, France, Italy and Spain are among those that have resumed use of the Oxford-AstraZeneca vaccine after Europe’s drug regulator said its initial investigation of possible side effects concluded the shot is safe and effective.

This is a developing story and will be updated shortly.

Articles You May Like

Why you should be wary of investing advice from celebrities like Kim Kardashian
46% of Americans continue to make this expensive credit card mistake
Here’s how advisors are helping clients slash their 2022 tax bill
Mortgage applications plummet 14% as higher interest rates and Hurricane Ian crush demand
Acuity Brands Trades Higher After Earnings Beat